Thursday, 4 August 2016

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

Patients with higher baseline neutrophil counts or high tumor expression of CSF3 (G-CSF), the growth factor for neutrophils, especially benefit from Avastin in a large exploratory cohort and two clinical trial cohorts.

Click here for abstract and full text links.

No comments:

Post a Comment